非肌层浸润性膀胱癌诊断后前4年健康相关生活质量:大型多中心前瞻性队列研究结果
基于多中心前瞻性UroLife队列(n=1019)及年龄性别匹配常模人群(n=490),评估非肌层浸润性膀胱癌诊断后6周、3、15、51个月健康相关生活质量。多数生活质量维度随时间稳定,变化仅具小临床意义;高级别、高EAU风险组、初始BCG治疗、女性及<65岁者在部分维度较差但差异少而短暂;与常模相比15个结局中6个临床相关较差,多数在51个月恢复。
要点
- 非肌层浸润性膀胱癌诊断后前4年多数生活质量维度保持稳定,观察到的变化仅具小临床意义。
- 高级别、高EAU风险组、初始BCG治疗、女性及<65岁者在部分维度生活质量较差,但差异少、小且短暂。
- 与常模人群相比,15个结局中6个临床相关较差,多数在51个月恢复,仅食欲减退和腹泻轻微症状持续。
核心结论
- 非肌层浸润性膀胱癌诊断后前4年未观察到生活质量显著变化。
- 分级、EAU风险组、初始治疗、复发状态、性别和年龄未对生活质量产生重要影响。
- 生活质量与一般人群基本相当,尤其在4年后。
研究设计与样本
- 多中心前瞻性队列UroLife,纳入非肌层浸润性膀胱癌患者n=1019,于诊断后6周(基线)、3、15、51个月收集数据。
- 纵向参考数据来自年龄和性别匹配的常模人群n=490。
- 采用EORTC QLQ-C30和EORTC QLQ-NMIBC24问卷评估癌症及NMIBC特异性生活质量结局(范围0-100),线性混合模型分析组内变化和组间差异。
主要发现
- 多数生活质量结局随时间保持稳定,观察到的变化仅具小临床意义。
- 失眠、社会功能及三个NMIBC特异性症状改善,而食欲和腹泻的轻微恶化持续至51个月。
- 高级别NMIBC、高EAU风险组、初始BCG治疗、女性及<65岁者在部分领域生活质量较差,但差异少、小且短暂。
- 复发状态间未观察到差异。
- 与常模人群相比,15个结局中6个临床相关较差,多数在51个月恢复,仅食欲减退和腹泻轻微症状例外。
关键数值与推荐
- 生活质量结局评分范围0-100。
- 与常模人群相比,15个结局中6个临床相关较差。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The health-related quality of life (HRQoL) of patients with non-muscle-invasive bladder cancer (NMIBC) may be impaired due to the chronic and burdensome disease course, but longitudinal data are limited. OBJECTIVE: To evaluate HRQoL outcomes during the first 4 yr after NMIBC diagnosis, and to compare HRQoL across patient characteristics and with a normative population. DESIGN, SETTING, AND PARTICIPANTS: Patients with NMIBC (n = 1019) were included from the multicentre prospective cohort UroLife. Data were collected at 6 wk (baseline), and 3, 15, and 51 mo after diagnosis. Longitudinal reference data were obtained from an age- and sex-matched normative population (n = 490). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Cancer- and NMIBC-specific HRQoL outcomes (range 0-100) were evaluated by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and EORTC QLQ-NMIBC24 questionnaires, respectively. Linear mixed modelling was used to analyse within-group changes and between-group differences. RESULTS AND LIMITATIONS: The majority of HRQoL outcomes remained stable over time. Observed changes were only of small clinical relevance. Improvements were noted in insomnia, social functioning, and three NMIBC-specific symptoms, while minor deteriorations in appetite and diarrhoea lasted until 51 mo. HRQoL in some domains was worse for high-grade NMIBC, high European Association of Urology (EAU) risk group, initial Bacillus Calmette-Guérin (BCG) treatment, being female, and being younger (<65 yr); yet differences were few, small, and temporary. No differences were observed across recurrence status. Compared with a normative population, clinically relevant worse scores were observed for six of 15 outcomes, which mostly recovered at 51 mo, except for minor symptoms of appetite loss and diarrhoea. CONCLUSIONS: No remarkable changes in HRQoL were observed during the first 4 yr after NMIBC diagnosis. Grade, EAU risk group, initial treatment, recurrence, sex, and age did not importantly affect HRQoL. HRQoL was largely comparable with that of the general population, especially after 4 yr. PATIENT SUMMARY: Quality of life is not largely affected during the first 4 yr after non-muscle-invasive bladder cancer diagnosis.
引用
- Beeren I, Klerks NE, Aben KK, et al. Health-related Quality of Life During the First 4 Years After Non-Muscle-invasive Bladder Cancer Diagnosis: Results of a Large Multicentre Prospective Cohort. Eur Urol Oncol. 2023. PMID: 37996278. doi:10.1016/j.euo.2023.11.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。